Acrivon Therapeutics, Inc. (ACRV) has 16 SEC Form 4 insider filings on record in the last 90 days. No insider purchases were filed — 8 sales totalling $40K. Most recent filing: Sept. 2, 2026.
| Date | Insider | Value | Shares | Stake | Pre-planned | Links |
|---|---|---|---|---|---|---|
| Sept. 2, 2026 filed Aug. 31, 2026 | Levin Michaela Chief Business Officer | $0 | 160,000 | +30% | No | |
|
|
||||||
| Aug. 27, 2026 filed Aug. 25, 2026 | Blume-Jensen Peter President and CEO | −$30,969 | 14,036 | −1% | No | |
|
|
||||||
| Aug. 20, 2026 filed Aug. 18, 2026 | Peterson Katharine Chief Accounting Officer | −$203 | 101 | −1% | No | |
|
|
||||||
| Aug. 20, 2026 filed Aug. 18, 2026 | Miller Mary Chief Legal Officer | −$372 | 185 | −0% | No | |
|
|
||||||
| Aug. 20, 2026 filed Aug. 18, 2026 | Gamelin Erick Chief Development Officer | −$804 | 400 | −1% | No | |
|
|
||||||
Showing the 5 most recent of 16 filings in the last 90 days.
Form 4 is the filing company officers, directors and 10% shareholders must submit to the SEC within two business days of trading their own company's stock. Open-market purchases generally carry more signal than sales, which are often scheduled in advance. More on how this works.
Real-time Telegram alerts the moment a Form 4 is filed. Filings shown here are delayed by 72 hours.
Start free